Reduction of urinary basic fibroblast growth factor using pentosan polysulphate sodium.
OBJECTIVE
To evaluate the use of pentosan polysulphate sodium (PPS) to reduce the level of urinary basic fibroblast growth factor (bFGF).


METHODS
Forty-one patients with a clam enterocystoplasty were randomized to receive either 200 mg three times daily of oral PPS (n = 21) or placebo (n = 20) for 6 weeks. Three patients acted as a cross-over study. Urinary bFGF was measured before and after treatment and the degree of symptomatic benefit assessed using a questionnaire.


RESULTS
There was no reduction in bFGF in the patients receiving placebo (P = 0.235) but there was a statistically significant reduction in bFGF (P = 0.0251) in the patients receiving PPS, most of whom were symptomatically improved, especially with regard to mucus production.


CONCLUSIONS
PPS may have a role in reducing urinary bFGF in patients with bladder tumours or following an enterocystoplasty and also in improving the quality of life of patients with a clam enterocystoplasty.
Barrington
J W
JW
Department of Urology, Cardiff Royal Infirmary, UK.
Fulford
S
S
Fraylin
L
L
Fish
R
R
Shelley
M
M
Stephenson
T P
TP
D000293:Adolescent; D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D002648:Child; D018592:Cross-Over Studies; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000652:urine*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010426:Pentosan Sulfuric Polyester / Q000627:therapeutic use*; D011182:Postoperative Care; D001749:Urinary Bladder Neoplasms / Q000601:surgery
D000925:Anticoagulants; D016222:Fibroblast Growth Factor 2; D010426:Pentosan Sulfuric Polyester